Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
FEMS Microbiology Immunology
|
October 1, 1992
Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response
R Rappuoli, M Pizza, A Covacci, et al.
Lancet (London, England)
|
June 27, 2001
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
K G Nicholson, A E Colegate, A Podda, et al.
Medical Microbiology and Immunology
|
November 30, 2002
Experience with the clinical development of influenza vaccines for potential pandemics
J M Wood, K G Nicholson, I Stephenson, et al.
Vaccine
|
August 5, 2000
Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster
M Minutello, C Zotti, S Orecchia, et al.
Blood
|
April 15, 1990
Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome
R Galanello, M A Melis, A Podda, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita
|
March 1, 1991
[A phase-I clinical trial of a new antitetanus/antidiphtheria vaccine for adults]
A Podda, N Vescia, D Donati, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
September 9, 2014
Acute Liver Failure Because of Wilson Disease With Overlapping Autoimmune Hepatitis Features: The Coexistence of Two Diseases?
Georgios Loudianos, Antonietta Zappu, Maria B Lepori, et al.
The Turkish Journal of Pediatrics
|
April 19, 2000
Safety, tolerability and immunogenicity of a Haemophilus influenzae type b vaccine containing aluminum phosphate adjuvant administered at 2, 3 and 4 months of age
G Kanra, S Viviani, K Yurdakök, et al.
Vaccine
|
August 26, 1999
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
S De Donato, D Granoff, M Minutello, et al.
The Journal of Pediatrics
|
August 1, 1995
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine
A Podda, G Bona, G Canciani, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
FEMS Microbiology Immunology
|
October 1, 1992
Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response
R Rappuoli, M Pizza, A Covacci, et al.
Lancet (London, England)
|
June 27, 2001
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
K G Nicholson, A E Colegate, A Podda, et al.
Medical Microbiology and Immunology
|
November 30, 2002
Experience with the clinical development of influenza vaccines for potential pandemics
J M Wood, K G Nicholson, I Stephenson, et al.
Vaccine
|
August 5, 2000
Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster
M Minutello, C Zotti, S Orecchia, et al.
Blood
|
April 15, 1990
Deletion delta-thalassemia: the 7.2 kb deletion of Corfu delta beta-thalassemia in a non-beta-thalassemia chromosome
R Galanello, M A Melis, A Podda, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita
|
March 1, 1991
[A phase-I clinical trial of a new antitetanus/antidiphtheria vaccine for adults]
A Podda, N Vescia, D Donati, et al.
Journal of Pediatric Gastroenterology and Nutrition
|
September 9, 2014
Acute Liver Failure Because of Wilson Disease With Overlapping Autoimmune Hepatitis Features: The Coexistence of Two Diseases?
Georgios Loudianos, Antonietta Zappu, Maria B Lepori, et al.
The Turkish Journal of Pediatrics
|
April 19, 2000
Safety, tolerability and immunogenicity of a Haemophilus influenzae type b vaccine containing aluminum phosphate adjuvant administered at 2, 3 and 4 months of age
G Kanra, S Viviani, K Yurdakök, et al.
Vaccine
|
August 26, 1999
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
S De Donato, D Granoff, M Minutello, et al.
The Journal of Pediatrics
|
August 1, 1995
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine
A Podda, G Bona, G Canciani, et al.
Page
of 6